Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H20O9 |
| Molecular Weight | 416.3781 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=C(O)C=CC3=C2OC=C(C3=O)C4=CC=C(O)C=C4
InChI
InChIKey=HKEAFJYKMMKDOR-VPRICQMDSA-N
InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1
| Molecular Formula | C21H20O9 |
| Molecular Weight | 416.3781 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Puerarin (7, 4’-dihydroxyisolavone-8-β-glucopyranoside) is an active isoflavone extracted from the roots of Pueraria lobata (Willd.) Ohwi. Puerarin is widely used in traditional Chinese medicine, and is clinically used in China for the treatment of coronary artery disease, heart failure, hypertension and myocardial infarction. It has been reported that puerarin had therapeutic effects on diabetes mellitus, arteriosclerosis and myocardial ischemia in animals. Puerarin demonstrated beta-adrenergic receptor blocking effect. On the other hand, puerarin stimulated alpha1-adrenoreceptor to increase glucose uptake into cultured C2C12 cells of mice. Puerarin has been investigated for the treatment (phase II clinical trials) of Alcohol Abuse, Rheumatoid Arthritis and Hypertension.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1914276 |
|||
Target ID: Tetrodotoxin resistant (TTXr) sodium current |
|||
Target ID: P97718 Gene ID: 11549.0 Gene Symbol: Adra1a Target Organism: Mus musculus (Mouse) |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.07 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25264914 |
9.984 mg single, oral dose: 9.984 mg route of administration: Oral experiment type: SINGLE co-administered: |
PUERARIN blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
85.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25264914 |
9.984 mg single, oral dose: 9.984 mg route of administration: Oral experiment type: SINGLE co-administered: |
PUERARIN blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25264914 |
9.984 mg single, oral dose: 9.984 mg route of administration: Oral experiment type: SINGLE co-administered: |
PUERARIN blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Puerarin protects mouse liver against nickel-induced oxidative stress and inflammation associated with the TLR4/p38/CREB pathway. | 2016-01-05 |
|
| Puerarin attenuates learning and memory impairments and inhibits oxidative stress in STZ-induced SAD mice. | 2015-12 |
|
| Protective effects of puerarin against tetrabromobisphenol a-induced apoptosis and cardiac developmental toxicity in zebrafish embryo-larvae. | 2015-09 |
|
| Impact of kudzu and puerarin on sperm function. | 2015-06 |
|
| Puerarin protects against lead-induced cytotoxicity in cultured primary rat proximal tubular cells. | 2014-10 |
|
| Puerarin ameliorates carbon tetrachloride-induced oxidative DNA damage and inflammation in mouse kidney through ERK/Nrf2/ARE pathway. | 2014-09 |
|
| Anti-diabetic effects of puerarin, isolated from Pueraria lobata (Willd.), on streptozotocin-diabetogenic mice through promoting insulin expression and ameliorating metabolic function. | 2013-10 |
|
| Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-γ expression and inhibition of PI3K/Akt pathway. | 2013-06 |
|
| Protective effect of puerarin on lead-induced mouse cognitive impairment via altering activities of acetyl cholinesterase, monoamine oxidase and nitric oxide synthase. | 2013-05 |
|
| Protective effects of puerarin on experimental chronic lead nephrotoxicity in immature female rats. | 2013-02 |
|
| Puerarin mediates hepatoprotection against CCl4-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function. | 2013-02 |
|
| Puerarin, a selective oestrogen receptor modulator, disrupts pregnancy in rats at pre-implantation stage. | 2012-11 |
|
| UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes. | 2012-11 |
|
| Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats. | 2011-12 |
|
| Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase. | 2011-11-15 |
|
| Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis. | 2011-07-15 |
|
| Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. | 2010-08 |
|
| Puerarin suppresses AGEs-induced inflammation in mouse mesangial cells: a possible pathway through the induction of heme oxygenase-1 expression. | 2010-04-15 |
|
| [Apoptosis of NB4 cells induced by flavonoids of puerarin in vitro]. | 2010-04 |
|
| Examining the genomic influence of skin antioxidants in vitro. | 2010 |
|
| Effect of puerarin on the expression of extracellular matrix in rats with streptozotocin-induced diabetic nephropathy. | 2009-09-19 |
|
| Phytoestrogens induce differential estrogen receptor beta-mediated responses in transfected MG-63 cells. | 2008-05-21 |
|
| [Effect of compound Puerarin on the collage IV in streptozotocin-induced diabetic nephropathy rats]. | 2008-04 |
|
| Protective effects of puerarin on carbon tetrachloride-induced hepatotoxicity. | 2007-10 |
|
| Herbal mixtures consisting of puerarin and either polyenylphosphatidylcholine or curcumin provide comprehensive protection against alcohol-related disorders in P rats receiving free choice water and 15% ethanol in pure water. | 2007-09 |
|
| Intestinal bacteria activate estrogenic effect of main constituents puerarin and daidzin of Pueraria thunbergiana. | 2006-12 |
|
| Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006-11 |
|
| Induction of apoptosis by puerarin in colon cancer HT-29 cells. | 2006-07-08 |
|
| Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. | 2006-07 |
|
| The Neuroprotection of puerarin against cerebral ischemia is associated with the prevention of apoptosis in rats. | 2005-07 |
|
| [Estrogen-like effects of puerarin and total isoflavones from Pueraria lobata]. | 2002-08 |
Patents
Sample Use Guides
400 mg once a day. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:03:33 GMT 2025
by
admin
on
Mon Mar 31 21:03:33 GMT 2025
|
| Record UNII |
Z9W8997416
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
3581 (Number of products:1)
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30958020
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
5281807
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
PUERARIN
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
380711
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
C033607
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
Z9W8997416
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
100000127786
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
DB12290
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
SUB33910
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY | |||
|
3681-99-0
Created by
admin on Mon Mar 31 21:03:33 GMT 2025 , Edited by admin on Mon Mar 31 21:03:33 GMT 2025
|
PRIMARY |